Healthcare Industry News: Oncotype DX
News Release - January 23, 2013
Strand Diagnostics appoints new PresidentFormer Genomic Health executive Laura Beggrow hired to advance commercialization of the know error® system
INDIANAPOLIS, Jan. 23, 2013 -- (Healthcare Sales & Marketing Network) -- Strand Diagnostics, LLC, maker of the know error® system, announced today the appointment of Laura Beggrow as President. She was recruited by Strand Diagnostics to drive the sales and marketing efforts of the company.
"We are very excited about adding Laura to our team," said Strand Diagnostics CEO, Ted Schenberg. "We expect that her experience in building out large-scale sales organizations, and her track record of driving growth in early-stage molecular diagnostics companies will help accelerate adoption of the know error® system as the new standard of care."
Prior to joining Strand Diagnostics, Beggrow served as Vice President of U.S. Sales and Marketing at Genomic Health. During her tenure, she was responsible for commercializing the company's groundbreaking Oncotype DX products in the breast and colon cancer markets, growing sales of the Oncotype DX test from $10 million to more than $200 million per year.
"Laura's background is a perfect fit for where we are as a company," said Schenberg. "Her experience in commercializing molecular diagnostic testing for breast and prostate cancers will be a tremendous asset as we look to grow adoption of the know error® system."
"I am extremely excited to join Strand Diagnostics," said Beggrow. "They have developed some very compelling products in a short period of time and established a solid foundation on which to build. Specimen provenance is an under-appreciated aspect of the diagnostic cycle, with as many as 3.5 percent of biopsies in certain clinical settings resulting in a diagnosis complicated by undetected specimen switches or contaminations. The know error® system gives healthcare providers a tool to ensure that the right diagnosis is assigned to the right patient at the right time and the right cost – and all of this begins with the right specimen. I look forward to working with this talented and dedicated team to eliminate diagnostic mistakes due to undetected provenance errors."
The know error® system compares the DNA profile of a biopsy specimen to the DNA profile of a reference sample taken via cheek swab. This process safeguards patients from diagnostic and treatment errors that may occur due to undetected switches or contamination of biopsy specimens during the complex diagnostic testing cycle for cancer.
About Strand Diagnostics
As a comprehensive provider of DNA testing services, Strand Diagnostics has a strong track record of using cutting-edge technology to solve complex problems in the criminal justice system and life sciences sector. The company's forensic division supports law enforcement agencies with forensic DNA identity testing services. Strand Diagnostics' healthcare division developed and markets the know error® system, which is used by physicians and laboratories to confirm specimen provenance as an integral component of the diagnostic testing cycle for cancer, ensuring patients are always matched with the appropriate diagnosis.
Source: Strand Diagnostics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.